-
A Comparison of the Biosimilar Accessibility in China, the EU, and the U.S.: China’s Biosimilars Commercialized at an Impressive Speed
PharmaSources/1°C
February 04, 2020
Biosimilars significantly reduce patients’ burden and boost the life science innovation to benefit more people!
-
After APIs, Carcinogens NDMA and NDEA Now Impacting Formulations
PharmaSources/Dishui Sinan
February 03, 2020
NMPA (CDE) released on its website the Technical Guidelines for the Research of Nitrosamine Impurities in Chemical Drugs (Draft for Comment) on Jan. 10, 2020.
-
Hengrui's Class 1 New Drug Fluzoparib has been Applied for New Clinical Trials
PharmaSources/Caicai
February 03, 2020
Sun Piaoyang’s Leaving Office Will Not Stop Hengrui from Moving Forward
-
Global pharmaceutical industry making efforts on the fight against Coronavirus
En-CPhI.CN
January 31, 2020
As the Coronavirus outbreak continues to grow in China and around the world, it has caused accumulated above 200 deaths in China and nearly 10 thound contracted cases in the world.
-
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus
PharmaSources/Wuxi Biologics
January 29, 2020
WuXi Biologics has stepped up its efforts in enabling the development of multiple neutralizing antibodies for Novel Coronavirus (2019-nCoV) with its integrated technology platforms.
-
Numbers of Drug Approval by FDA, EMA and NMPA in 2019
En-CPhI.Cn
January 23, 2020
A quick review of drug approval in the past 2019 by NMPA, EMA and FDA.
-
LABWorld China 2020 is Gearing Up - “Future Labs” Leading “Future Pharmaceuticals”
En-CPhI.CN
January 22, 2020
The National Medical Products Administration (NMPA) announced the first 45 key laboratories in June 2019 and mentioned that the construction of national-level innovative key laboratories would play a guiding and demonstrated role in improving drug sci-tec
-
Roche HER2-ADC Enmetrastuzumab has been approved for marketing in China
En-CPhI.CN
January 19, 2020
Detailed story will be updated soon, please stay tuned with us.
-
A Review of the Chinese Pharmaceutical Policies/Events in 2019
PharmaSources/Suyi
January 19, 2020
5 policies in 2019 will affect China’s pharmaceutical market in 2020, which mainly involve China’s national medical insurance payment and pharmaceutical product cost control.
-
FDF China to be held in June to boost Chinese pharmaceutical enterprises to "go global" and promote the innovation and development of industry
PharmaSources/prnasia
January 16, 2020
FDF China, collocated with CPhI China, will be held from June 22-24, 2020 at Shanghai New International Expo Centre (SNIEC).